Takeda (TSE:4502/NYSE:TAK), a global values-based R&D-driven biopharmaceutical leader headquartered in Japan, translates science into innovative medicines. It focuses its R&D efforts on four therapeutic areas: oncology, rare diseases, neuroscience and gastroenterology. It also makes R&D investments in plasma-derived therapies and vaccines. Takeda is focusing on developing innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging enhanced collaborative R&D engines and capabilities to create a modality-diverse pipeline. Its employees are committed to improving quality of life for patients and to working with healthcare partners in some 80 countries.
Global warming is helping mosquitoes to spread mosquito-borne diseases further around the world, collaborative investment is required to solve this issue.
Highly individualized medicine is now within reach. We highlight three examples that support the contact between patients and doctors using digital tools.
Data is at the heart of the Fourth Industrial Revolution. In a time of global crisis and economic uncertainty, its management, use and sharing are crucial for the resilience of economies ...
The Platform for Shaping the Future of Health and Healthcare engages stakeholders in new models of public private collaboration to identify and scale up solutions for more resilient, effi...
